Arovella Therapeutics Limited

ASX:ALA Stock Report

Market Cap: AU$189.7m

Arovella Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Arovella Therapeutics has a total shareholder equity of A$11.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$13.3M and A$2.1M respectively.

Key information

0%

Debt to equity ratio

AU$0

Debt

Interest coverage ration/a
CashAU$12.71m
EquityAU$11.23m
Total liabilitiesAU$2.06m
Total assetsAU$13.28m

Recent financial health updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Financial Position Analysis

Short Term Liabilities: ALA's short term assets (A$13.2M) exceed its short term liabilities (A$2.0M).

Long Term Liabilities: ALA's short term assets (A$13.2M) exceed its long term liabilities (A$15.9K).


Debt to Equity History and Analysis

Debt Level: ALA is debt free.

Reducing Debt: ALA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALA has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 14% each year.


Discover healthy companies